BMS to ImClone: We just might walk

"You should never fall in love with an asset." Those are the words of Bristol-Myers Squibb's CFO, who assured investors today that his company won't be despondent if ImClone Systems ultimately rejects its buyout offer.

Part of the high-stakes bluffing game--part poker, part chicken--that these takeover bids often become? Maybe. Or maybe Jean-Marc Huet does, as he said, "understand the business very well." Maybe he knows enough about ImClone to see that a deal wouldn't be a good deal under all circumstances. "[T]here are situations in which we are willing to walk away," he said.

You'll recall that Bristol offered $60 a share for its partner-in-Erbitux, and ImClone promptly called that price inadequate. Just last week, Chairman Carl Icahn announced that he had a major pharma company just offstage, $70-per-share offer in hand. Since then, Icahn and Bristol CEO Jim Cornelius have been sparring over buyout protocol and, more importantly, Bristol's rights to an ImClone follow-up to Erbitux.

This take-it-or-leave-it tale is the latest salvo--but certainly not the last. Stay tuned.

- see the Star-Ledger story
- check out the item at the WSJ Health Blog

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.